JP2020530120A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530120A5 JP2020530120A5 JP2020507022A JP2020507022A JP2020530120A5 JP 2020530120 A5 JP2020530120 A5 JP 2020530120A5 JP 2020507022 A JP2020507022 A JP 2020507022A JP 2020507022 A JP2020507022 A JP 2020507022A JP 2020530120 A5 JP2020530120 A5 JP 2020530120A5
- Authority
- JP
- Japan
- Prior art keywords
- biomarker
- subject
- heart failure
- biological sample
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 claims 33
- 238000000034 method Methods 0.000 claims 15
- 239000012472 biological sample Substances 0.000 claims 14
- 206010019280 Heart failures Diseases 0.000 claims 13
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 claims 5
- 102100038297 Kallikrein-1 Human genes 0.000 claims 5
- 210000000214 mouth Anatomy 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 210000003296 saliva Anatomy 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- -1 KV110 Proteins 0.000 claims 3
- 102100030972 Coatomer subunit beta Human genes 0.000 claims 2
- 101000919970 Homo sapiens Coatomer subunit beta Proteins 0.000 claims 2
- 101001055314 Homo sapiens Immunoglobulin heavy constant alpha 2 Proteins 0.000 claims 2
- 102100026216 Immunoglobulin heavy constant alpha 2 Human genes 0.000 claims 2
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 claims 2
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 claims 2
- 206010036790 Productive cough Diseases 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 210000003802 sputum Anatomy 0.000 claims 2
- 208000024794 sputum Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 102100037355 Chromosome alignment-maintaining phosphoprotein 1 Human genes 0.000 claims 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 1
- 102100023319 Dihydrolipoyl dehydrogenase, mitochondrial Human genes 0.000 claims 1
- 101710144432 Dihydrolipoyl dehydrogenase, mitochondrial Proteins 0.000 claims 1
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 claims 1
- 101000880066 Homo sapiens Chromosome alignment-maintaining phosphoprotein 1 Proteins 0.000 claims 1
- 208000008253 Systolic Heart Failure Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017903138 | 2017-08-08 | ||
| AU2017903138A AU2017903138A0 (en) | 2017-08-08 | Methods for Diagnosis of Early Stage Heart Failure | |
| PCT/AU2018/050827 WO2019028507A1 (en) | 2017-08-08 | 2018-08-08 | METHODS OF DIAGNOSING PRECOCUS STAGES OF CARDIAC INSUFFICIENCY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530120A JP2020530120A (ja) | 2020-10-15 |
| JP2020530120A5 true JP2020530120A5 (https=) | 2021-09-16 |
| JP7414281B2 JP7414281B2 (ja) | 2024-01-16 |
Family
ID=65273054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507022A Active JP7414281B2 (ja) | 2017-08-08 | 2018-08-08 | 初期心不全の診断方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200174021A1 (https=) |
| EP (1) | EP3665483A4 (https=) |
| JP (1) | JP7414281B2 (https=) |
| CN (1) | CN111465857A (https=) |
| AU (2) | AU2018315056B2 (https=) |
| WO (1) | WO2019028507A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021245459A1 (en) * | 2020-06-03 | 2021-12-09 | Esn Cleer | Biomarker identification for imminent and/or impending heart failure |
| EP4356142A4 (en) | 2021-06-16 | 2025-07-23 | Endothelium Scanning Nanotechnology Ltd | BIOMARKERS AND DRUG COMBINATIONS FOR THE PREDICTION OF HEART FAILURE |
| CN115327129A (zh) * | 2022-07-05 | 2022-11-11 | 上海交通大学医学院附属上海儿童医学中心 | 一种血浆分子标志物犬尿氨酸在早期心力衰竭检测中的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002094870A2 (en) * | 2000-11-02 | 2002-11-28 | Curagen Corporation | Proteins and nucleic acids encoding same |
| WO2002061131A2 (en) * | 2000-12-04 | 2002-08-08 | Bristol-Myers Squibb Company | Human single nucleotide polymorphisms |
| US20040033582A1 (en) * | 2002-06-03 | 2004-02-19 | Manling-Ma Edmonds | Human single nucleotide polymorphisms |
| TW200413539A (en) * | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Genes and polypeptides relating to prostate cancers |
| JP2005110602A (ja) * | 2003-10-09 | 2005-04-28 | Sumitomo Pharmaceut Co Ltd | アトピー性皮膚炎の疾患マーカー及びその利用 |
| WO2006008002A2 (en) * | 2004-07-23 | 2006-01-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with kallikrein 1 (klk1) |
| BRPI0513897A (pt) * | 2004-07-29 | 2008-05-20 | Stem Cell Innovations Inc | diferenciação de células-tronco |
| EP1722232A1 (en) * | 2005-05-09 | 2006-11-15 | F.Hoffmann-La Roche Ag | Devices and methods for diagnosing or predicting early stage cardiac dysfunctions |
| JP5219819B2 (ja) * | 2005-10-21 | 2013-06-26 | カタリスト・バイオサイエンシーズ・インコーポレイテッド | 補体活性化を阻害する修飾プロテアーゼ |
| US20080057590A1 (en) * | 2006-06-07 | 2008-03-06 | Mickey Urdea | Markers associated with arteriovascular events and methods of use thereof |
| JP2009541287A (ja) * | 2006-06-20 | 2009-11-26 | リポペプチド・アクチエボラーグ | 抗癌剤としてのカテリシジン抗菌タンパク質（ｈＣＡＰ１８）の使用 |
| WO2008000067A1 (en) * | 2006-06-26 | 2008-01-03 | Vasogen Ireland Limited | Treatment of mild chronic heart failure in human patients |
| CA2791144C (en) * | 2006-07-05 | 2019-04-09 | Catalyst Biosciences, Inc. | Protease screening methods and proteases identified thereby |
| SG175602A1 (en) * | 2006-07-05 | 2011-11-28 | Catalyst Biosciences Inc | Protease screening methods and proteases identified thereby |
| US20080300170A1 (en) * | 2006-09-01 | 2008-12-04 | Cohava Gelber | Compositions and methods for diagnosis and treatment for type 2 diabetes |
| US20100267052A1 (en) * | 2006-09-01 | 2010-10-21 | American Type Culture Collection | Compositions and methods for diagnosis and treatment of type 2 diabetes |
| GB2444410B (en) * | 2006-11-30 | 2011-08-24 | Navigenics Inc | Genetic analysis systems and methods |
| ZA200903761B (en) * | 2006-11-30 | 2010-08-25 | Navigenics Inc | Genetic analysis systems and methods |
| CN102858985A (zh) * | 2009-07-24 | 2013-01-02 | 西格马-奥尔德里奇有限责任公司 | 基因组编辑方法 |
| WO2011133770A2 (en) * | 2010-04-21 | 2011-10-27 | Board Of Regents Of The University Of Texas System | Salivary protein markers for detection of breast cancer |
| JP2014505259A (ja) * | 2011-02-03 | 2014-02-27 | アボット・ラボラトリーズ | 慢性心不全における予後診断および診断の方法 |
| WO2013083781A2 (en) * | 2011-12-08 | 2013-06-13 | Pronota N.V. | Biomarkers and test panels useful in systemic inflammatory conditions |
| US20150072360A1 (en) * | 2011-12-14 | 2015-03-12 | The Johns Hopkins University | Biomarkers of pulmonary hypertension |
| US10131709B2 (en) * | 2011-12-28 | 2018-11-20 | Immunoqure Ag | Nucleic acid molecules encoding monoclonal antibodies specific for IL-22 |
| AU2013293270B2 (en) * | 2012-07-25 | 2018-08-16 | Massachusetts Institute Of Technology | Inducible DNA binding proteins and genome perturbation tools and applications thereof |
| WO2014028734A1 (en) * | 2012-08-15 | 2014-02-20 | The Procter & Gamble Company | Human ex vivo skin model and use in methods of identifying modulators of skin inflammation |
| WO2014193999A2 (en) * | 2013-05-28 | 2014-12-04 | Caris Science, Inc. | Biomarker methods and compositions |
| CN104049082B (zh) * | 2014-05-30 | 2016-03-16 | 华中科技大学同济医学院附属同济医院 | 人组织激肽释放酶活性检测试剂盒及其应用 |
| CN105987998B (zh) * | 2015-01-30 | 2017-12-29 | 江苏众红生物工程创药研究院有限公司 | 人组织激肽释放酶1elisa定量检测试剂盒 |
| US11041865B2 (en) * | 2015-02-20 | 2021-06-22 | The Johns Hopkins University | Biomarkers of myocardial injury |
-
2018
- 2018-08-08 JP JP2020507022A patent/JP7414281B2/ja active Active
- 2018-08-08 CN CN201880063136.3A patent/CN111465857A/zh active Pending
- 2018-08-08 AU AU2018315056A patent/AU2018315056B2/en active Active
- 2018-08-08 EP EP18844704.9A patent/EP3665483A4/en not_active Withdrawn
- 2018-08-08 WO PCT/AU2018/050827 patent/WO2019028507A1/en not_active Ceased
- 2018-08-08 US US16/636,403 patent/US20200174021A1/en not_active Abandoned
-
2021
- 2021-09-13 AU AU2021232662A patent/AU2021232662B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ashton et al. | The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers | |
| Ding et al. | Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019 | |
| Pizarro et al. | Circulating progenitor cells and vascular dysfunction in chronic obstructive pulmonary disease | |
| Levin et al. | Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT) | |
| Abe et al. | Liver dysfunction assessed by model for end-stage liver disease excluding INR (MELD-XI) scoring system predicts adverse prognosis in heart failure | |
| Spengler et al. | Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques | |
| Ljungberg et al. | Proteomic biomarkers for incident aortic stenosis requiring valvular replacement | |
| JP2020530120A5 (https=) | ||
| JP2013513387A5 (https=) | ||
| US20190180846A1 (en) | System and method for analysis of biological data | |
| Díaz-Jiménez et al. | Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution | |
| Wu et al. | Development of a highly sensitive glycan microarray for quantifying AFP-L3 for early prediction of hepatitis B virus–related hepatocellular carcinoma | |
| JP2016520192A5 (https=) | ||
| Reque et al. | Pulmonary hypertension is an independent predictor of cardiovascular events and mortality in haemodialysis patients | |
| Artunc et al. | Plasma concentrations of the vasoactive peptide fragments mid-regional pro-adrenomedullin, C-terminal pro-endothelin 1 and copeptin in hemodialysis patients: associated factors and prediction of mortality | |
| Park et al. | The 2016 ASE/EACVI recommendations may be able to more accurately identify patients at risk for diastolic dysfunction in living donor liver transplantation | |
| JP2020514689A5 (https=) | ||
| JP2016526167A5 (https=) | ||
| Libby et al. | Whole blood transcript and protein abundance of the vascular endothelial growth factor family relate to cognitive performance | |
| Papaioannou et al. | Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE) | |
| Chen et al. | C-reactive protein and N-terminal prohormone brain natriuretic peptide as biomarkers in acute exacerbations of COPD leading to hospitalizations | |
| Ko et al. | Undiagnosed airflow limitation is common in patients with coronary artery disease and associated with cardiac stress | |
| Vigil et al. | Predictors of a rapid decline of renal function in patients with chronic kidney disease referred to a nephrology outpatient clinic: a longitudinal study | |
| Saisho et al. | C-reactive protein, high-molecular-weight adiponectin and development of metabolic syndrome in the Japanese general population: a longitudinal cohort study | |
| Sánchez et al. | Utility of the WHO dengue guidelines in pediatric immunological studies |